Crystalline forms of a PI3K inhibitor
View Patent ↗The present invention is related to crystalline forms of (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one which is a PI3K inhibitor useful in the treatment of cancer and other diseases.
1. A method of treating a disease in a patient, wherein said disease is arthritis, myasthenia gravis, multiple sclerosis, or Sjoegren's syndrome, comprising administering to said patient a therapeutically effective amount of a crystalline form of the compound (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one which is hydrated, or a crystalline form of the compound (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one which is Form X.
2. A method of treating an immune-based disease in a patient, wherein said immune-based disease is rheumatoid arthritis, glomerulonephritis, lupus, inflammation related to rheumatoid arthritis, inflammation related to glomerulonephritis, or inflammation related to lupus, comprising administering to said patient a therapeutically effective amount of a crystalline form of the compound (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one which is hydrated, or a crystalline form of the compound (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one which is Form X.
3. A method of treating B cell lymphoma in a patient, comprising administering to said patient a therapeutically effective amount of a crystalline form of the compound (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one which is hydrated, or a crystalline form of the compound (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one which is Form X.
4. The method of claim 1 , wherein the method comprises administering to said patient a therapeutically effective amount of a crystalline form of the compound (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one which is hydrated.
5. The method of claim 4 , wherein said disease is arthritis.
6. The method of claim 4 , wherein said disease is myasthenia gravis.
7. The method of claim 4 , wherein said disease is multiple sclerosis.
8. The method of claim 4 , wherein said disease is Sjoegren's syndrome.
9. The method of claim 2 , wherein the method comprises administering to said patient a therapeutically effective amount of a crystalline form of the compound (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one which is hydrated.
10. The method of claim 9 , wherein said immune-based disease is rheumatoid arthritis.
11. The method of claim 9 , wherein said immune-based disease is glomerulonephritis.
12. The method of claim 9 , wherein said immune-based disease is lupus.
13. The method of claim 9 , wherein said immune-based disease is inflammation related to rheumatoid arthritis, inflammation related to glomerulonephritis, or inflammation related to lupus.
14. The method of claim 3 , wherein the method comprises administering to said patient a therapeutically effective amount of a crystalline form of the compound (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one which is hydrated.
15. The method of claim 14 , wherein said B cell lymphoma is diffuse large B cell lymphoma.
16. The method of claim 14 , wherein said B cell lymphoma is activated B-cell like (ABC) diffuse large B cell lymphoma.
17. The method of claim 14 , wherein said B cell lymphoma is germinal center B cell (GCB) diffuse large B cell lymphoma.
18. The method of claim 1 , wherein the method comprises administering to said patient a therapeutically effective amount of a crystalline form of the compound (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one which is Form X.
19. The method of claim 18 , wherein said disease is arthritis.
20. The method of claim 18 , wherein said disease is myasthenia gravis.
21. The method of claim 18 , wherein said disease is multiple sclerosis.
22. The method of claim 18 , wherein said disease is Sjoegren's syndrome.
23. The method of claim 2 , wherein the method comprises administering to said patient a therapeutically effective amount of a crystalline form of the compound (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one which is Form X.
24. The method of claim 23 , wherein said immune-based disease is rheumatoid arthritis.
25. The method of claim 23 , wherein said immune-based disease is glomerulonephritis.
26. The method of claim 23 , wherein said immune-based disease is lupus.
27. The method of claim 23 , wherein said immune-based disease is inflammation related to rheumatoid arthritis, inflammation related to glomerulonephritis, or inflammation related to lupus.
28. The method of claim 3 , wherein the method comprises administering to said patient a therapeutically effective amount of a crystalline form of the compound (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one which is Form X.
29. The method of claim 28 , wherein said B cell lymphoma is diffuse large B cell lymphoma.
30. The method of claim 28 , wherein said B cell lymphoma is activated B-cell like (ABC) diffuse large B cell lymphoma.
31. The method of claim 28 , wherein said B cell lymphoma is germinal center B cell (GCB) diffuse large B cell lymphoma.